A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-03-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00211276
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Pacific Coast Hematology/Oncology, Fountain Valley, California, United States
A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Elective Colonoscopy
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-12-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT00209534
A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Minor Surgical Procedures
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2015-01-09
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT00209560
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT00211185
- Locations
- 🇺🇸
Hematology Oncology Associates of IL, Chicago, Illinois, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
A Study of AQUAVAN® Injection for Sedation in Elderly Patients Undergoing Flexible Bronchoscopy
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT00209586
Comparison of AQUAVAN® Injection to DISOPRIVAN® Injectable Emulsion for Anesthesia During Coronary Artery Surgery
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00209521
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2008-03-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00211198
- Locations
- 🇺🇸
New England Medical Center, Boston, Massachusetts, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University Hospitals of Cleveland, Cleveland, Ohio, United States
2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2008-11-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT00209508
Study to Assess Safety and Efficacy of AQUAVAN® Injection for Sedation During Cardiac Catheterization
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2008-11-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT00209547
A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Elderly Patients Undergoing Elective Colonoscopy
Phase 2
Terminated
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00209599
© Copyright 2024. All Rights Reserved by MedPath